Abbott Laboratories, current enterprise value calculation

Current share price (P)	$128.54
No. shares of common stock outstanding	1,738,871,947
US$ in millions
Common equity (market value)¹	223,515)
Add: Preferred shares, one dollar par value, none issued (per books)	—)
Add: Noncontrolling interests in subsidiaries (per books)	237)
Total equity	223,752)
Add: Short-term borrowings (per books)	—)
Add: Current portion of long-term debt (per books)	1,500)
Add: Long-term debt, excluding current portion (per books)	12,625)
Total equity and debt	237,877)
Less: Cash and cash equivalents	7,616)
Less: Investments, primarily bank time deposits and U.S. treasury bills	351)
Enterprise value (EV)	229,910)

Based on: 10-K (reporting date: 2024-12-31).

¹ Common equity (market value) = Share price × No. shares of common stock outstanding
= 128.54 × 1,738,871,947

Abbott Laboratories, EV calculation

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Share price^1, 2	$134.92	$114.01	$106.74	$116.79	$123.04
No. shares of common stock outstanding¹	1,734,323,411	1,735,184,289	1,737,946,233	1,763,482,267	1,771,529,358
US$ in millions
Common equity (market value)³	233,995)	197,828)	185,508)	205,957)	217,969)
Add: Preferred shares, one dollar par value, none issued (book value)	—)	—)	—)	—)	—)
Add: Noncontrolling interests in subsidiaries (book value)	237)	224)	219)	222)	219)
Total equity	234,232)	198,052)	185,727)	206,179)	218,188)
Add: Short-term borrowings (book value)	—)	—)	—)	—)	213)
Add: Current portion of long-term debt (book value)	1,500)	1,080)	2,251)	754)	7)
Add: Long-term debt, excluding current portion (book value)	12,625)	13,599)	14,522)	17,296)	18,527)
Total equity and debt	248,357)	212,731)	202,500)	224,229)	236,935)
Less: Cash and cash equivalents	7,616)	6,896)	9,882)	9,799)	6,838)
Less: Investments, primarily bank time deposits and U.S. treasury bills	351)	383)	288)	450)	310)
Enterprise value (EV)	240,390)	205,452)	192,330)	213,980)	229,787)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ Data adjusted for splits and stock dividends.

² Closing price as at the filing date of Abbott Laboratories Annual Report.

³ 2024 Calculation
Common equity (market value) = Share price × No. shares of common stock outstanding
= 134.92 × 1,734,323,411

The financial data reveals several notable trends in the equity and overall valuation metrics over the five-year period from 2020 to 2024.

Common Equity (Market Value): There is a fluctuating trend in common equity values. After a decline from approximately 218 billion US dollars in 2020 to about 185.5 billion by the end of 2022, a recovery phase is evident. The market value rises to nearly 198 billion in 2023 and further increases to approximately 234 billion in 2024, surpassing the initial 2020 level.
Total Equity: Total equity mirrors the trend observed in common equity with an initial downward movement from 218.2 billion in 2020 to 185.7 billion in 2022. Subsequently, equity levels improved to around 198 billion in 2023, reaching 234.2 billion in 2024. These figures suggest a strong recovery and growth in shareholder equity during the last two years.
Total Equity and Debt: This combined metric shows a decline from 237 billion in 2020 to roughly 202.5 billion in 2022, followed by a consistent increase through 2023 and 2024, peaking at 248.4 billion. The overall pattern suggests a reduction in combined equity and debt initially, then a material improvement, potentially reflecting changes in capital structure or financing activities.
Enterprise Value (EV): The enterprise value experiences a similar pattern with a downward trend from 229.8 billion in 2020 to 192.3 billion in 2022. It then increases in the following years to over 240 billion in 2024, indicating enhanced market perception or operational improvements driving higher valuations.

In summary, the data exhibits a consistent decline across all key financial measures through 2022, followed by a recovery and growth phase in 2023 and 2024. The growth surpasses previous levels, indicating positive developments influencing market value, equity, and overall enterprise valuation during the later years. This pattern could reflect strategic interventions, market conditions, or improved financial performance contributing to increased investor confidence and capitalization.

Download chart

Abbott Laboratories (NYSE:ABT)

Enterprise Value (EV)

Current Enterprise Value (EV)

Historical Enterprise Value (EV)